New results from a pooled analysis of patients with previously treated EGFR-mutated NSCLC in the TROPION-Lung05 and TROPION-Lung01 trials will be featured in a late-breaking presentation at the ...

Reported 100% of Acute Myeloid Leukemia (AML) patients treated in INB-100 remain in complete remission (CR) at the 2024 ...

Biologics License Application for cosibelimab under review by U.S. FDA PDUFA goal date of December 28, 2024 WALTHAM, Mass., ...

News in early breast cancer this year was marked by updated U.S. Preventive Services Task Force (USPSTF) screening ...

EMA granted clearance to advancebelrestotug 400mg + dostarlimab as recommended Phase 3 dose and activate GALAXIES Lung-301 clinical sites in ...

evaluating IO102-IO103 in combination with pembrolizumab in the first-line treatment of patients with metastatic disease were presented at the 2024 European Society of Medical Oncology (ESMO) Congress ...

Susan Galbraith-- Executive Vice President, Oncology Research and Development Thank you, Dave. In September, we showcased important data at the World Congress on Lung Cancer and the European Society ...

BillionToOne, a next-generation molecular diagnostics company, announces three new executive appointments to support its expanding prenatal screening and oncology diagnostics business. Judy Wong joins ...

A nurse-led service at Oxford University Hospitals has been praised for its "safe, effective, and highly efficient" patient care.

With one of the largest oncology research teams in the industry, BeiGene has demonstrated strengths in translational small ...

Obe-cel in r/r adult B-ALL – The FELIX Study and regulatory updates Obe-cel is under regulatory review in both the EU and the UK, with marketing authorization submissions accepted by the European ...